Tradestie Institutional Equity Comparison Engine
CVM vs AGEN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
AGEN Overall Edge
AGEN Captures Institutional Edge (3โ1 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Agenus Inc. (AGEN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CVM trades at 23.0x Forward P/E with 0.0% operating margin (-62.7% YoY revenue) versus AGEN at 3.7x Forward P/E and 38.9% operating margin (+4.1% YoY). In options structure, CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro) against AGEN sits in BREAKDOWN (11th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CVM 23.0x vs AGEN 3.7x Fwd P/E
Growth & Margin Winner
AGEN
Op Margin 0.0% vs 38.9% ยท YoY -62.7% vs +4.1%
Momentum & Technical Winner
AGEN
1Y -77.5% vs +46.4% ยท 52W Pos 10% vs 48%
Options & Structure Winner
AGEN
BREAKDOWN (N/A IV) vs BREAKDOWN (11th %ile IV)
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.59
+24.22% 1D
Market Cap
$20.9M
1M Return
-11.17%
1Y Return
-77.48%
Forward P/E
23.0x
Unified AI Score
56.6 / 100
HOLD
Tech 60.0
Fund 54.0
Flow 50.0
Mom 60.0
AGEN
NASDAQ
Agenus Inc.
Biological Products, (No Disgnostic Substances)
$6.34
-5.79% 1D
Market Cap
$310.8M
1M Return
+4.97%
1Y Return
+46.42%
Forward P/E
3.7x
Unified AI Score
51.5 / 100
HOLD
Tech 49.0
Fund 55.0
Flow 66.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CVM -77.48%
AGEN +46.42%
Spread: +122.06 pp (AGEN Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CVM Revenue | AGEN Revenue | CVM Op. Margin | AGEN Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | N/A | $40M | N/A | -336.6% | AGEN |
| FY2019 | N/A | $150M | N/A | -46.7% | AGEN |
| FY2020 | N/A | $90M | N/A | -133.0% | AGEN |
| FY2021 | N/A | $300M | N/A | 8.7% | AGEN |
| FY2022 | N/A | $100M | N/A | -183.0% | AGEN |
| FY2023 | N/A | $160M | N/A | -102.1% | AGEN |
| FY2024 | N/A | $100M | N/A | -116.4% | AGEN |
| FY2025 | N/A | $110M | N/A | -17.7% | AGEN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CVM | AGEN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $20.9M | $310.8M | Larger Scale | AGEN |
| Trailing P/E Ratio Valuation | 23.0x | 29.9x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | 23.0x | 3.7x | Lower Multiple | AGEN |
| Revenue Growth (YoY) Growth | -62.7% | +4.1% | Higher Growth | AGEN |
| Operating Margin (TTM) Profitability | 0.0% | 38.9% | Higher Margin | AGEN |
| Net Profit Margin Profitability | 0.0% | 30.8% | Higher Margin | AGEN |
| Return on Equity (ROE) Capital Efficiency | -252.5% | -1278.8% | Higher ROE | CVM |
| 52-Week Range Position Momentum | 10% ($1โ$8) | 48% ($3โ$10) | Stronger Trend | AGEN |
| Beta / 30D Volatility Risk Regime | 0.65ฮฒ ยท 120% Vol | 1.60ฮฒ ยท 76% Vol | Lower Realized Risk | AGEN |
| Unified Institutional Score Composite Signal | 56.6 / 100 (HOLD) | 51.5 / 100 (HOLD) | Higher Composite | CVM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CVM vs AGEN Buy Guide
CVM
BREAKDOWN
29d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
AGEN
BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CVM nor AGEN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.